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S U M M A R Y
There is currently an emerging outbreak of yellow fever in Angola. Cases in infected travellers have been
reported in a number of other African countries, as well as in China, representing the ﬁrst ever
documented cases of yellow fever in Asia. There is a large Chinese workforce in Angola, many of whom
may be unvaccinated, increasing the risk of ongoing importation of yellow fever into Asia via busy
commercial airline routes. Large parts of the region are hyperendemic for the related Flavivirus dengue
and are widely infested by Aedes aegypti, the primary mosquito vector of urban yellow fever
transmission. The combination of sustained introduction of viraemic travellers, an ecology conducive to
local transmission, and an unimmunized population raises the possibility of a yellow fever epidemic in
Asia. This represents a major global health threat, particularly in the context of a depleted emergency
vaccine stockpile and untested surveillance systems in the region. In this review, the potential for a
yellow fever outbreak in Asia is discussed with reference to the ecological and historical forces that have
shaped global yellow fever epidemiology. The limitations of surveillance and vector control in the region
are highlighted, and priorities for outbreak preparedness and response are suggested.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. A yellow fever outbreak emerges in Africa
On January 22, 2016, the internet-based disease outbreak
reporting system of the International Society for Infectious
Diseases – ProMED – posted an alert of 23 cases of yellow fever
(YF) amongst locals, as well as Congolese and Eritreans, in a heavily
populated suburb of Luanda, the Angolan capital.1 This was based
on an ofﬁcial Angolan Ministry of Health announcement. Three
days later, the number of suspected cases had grown to 99
(26 conﬁrmed), including eight deaths. On January 29, ProMED
reported additional cases in southern Huila Province nearly
1000 km from Luanda.2 Over the following weeks, a major urban
YF epidemic unfolded in Angola, and by April 10, a total of
1751 suspected cases (582 laboratory-conﬁrmed) with 242 deaths
had been reported. The outbreak is widespread, involving
59 districts in 12 of the 18 provinces in the country, including
the capital Luanda, which has recorded 406 conﬁrmed cases. Three
conﬁrmed cases in neighbouring Democratic Republic of CongoDOI of original article: http://dx.doi.org/10.1016/j.ijid.2016.05.001
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1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).have been connected with the Angolan outbreak,3 and infected
travellers have been reported in Kenya.4
Of major concern, the ﬁrst YF cases have been reported in Asia,
occurring in infected travellers from Angola. By April 10,
10 laboratory-conﬁrmed cases had been imported into China,
including six in Fujian Province, an area where dengue transmis-
sion has occurred.5 With a large expatriate Chinese community in
Angola, it is likely that additional undetected cases may have been
imported. If ongoing introduction of cases occurs in areas with a
high density of the urban YF mosquito vector, Aedes aegypti, it is
possible that local transmission could occur in China and
potentially spread to Southeast Asia.
Approximately two billion people live in Ae aegypti-infested
countries in Asia. The prospect of a YF introduction into this
unvaccinated population poses a major global health threat. In this
review, the potential for a YF outbreak in Asia is discussed in the
context of the ecological and historical forces that have shaped
global YF epidemiology. The aim is to draw attention to this
emerging epidemic and to provide impetus for the necessary
public health response.
PubMed was searched for papers written in English with the
search terms ‘‘yellow fever’’ and ‘‘Aedes aegypti’’, and all articles
that focused on epidemiology, recent outbreaks, and control andociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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website and Google Scholar were also searched for epidemiological
reports. The bibliographies of review articles and other selected
articles were scanned for other relevant references.
2. The ecology and clinical manifestations of yellow fever
YF is a viral haemorrhagic fever transmitted by mosquitoes. The
YF virus (YFV) is the prototype virus of the family Flaviviridae, a
group that includes the epidemic arthropod-borne viruses causing
dengue, Japanese encephalitis (JE), and Zika, amongst others. YF is
enzootic in rainforests of Africa and South America, and is
maintained in sylvatic transmission cycles between monkeys
and arboreal mosquitoes. Sporadic human infection can occur after
intrusion into this ‘jungle cycle’ through occupational or recrea-
tional exposure to infected mosquitoes, resulting in single cases or
limited sylvatic outbreaks. In South America, this may spill over
into nearby towns to enter an inter-human urban cycle. In the wet
African savannah, where mosquito vectors reach high densities in
the rainy season and overlap with areas of human activity, there is
intense enzootic transmission with increased risk of human
infection. Inter-human transmission that occurs as a result of
these epizootics is usually self-limited, but can lead to the
emergence of rural epidemics. This is known as the intermediate
cycle, or ‘zone of emergence,’ because extension of an epizootic
into dry savannah areas with larger human and domestic vector
populations may establish an urban epidemic cycle that can lead to
explosive outbreaks.
Ae aegypti is the vector for urban YF epidemics in both Africa
and South America, and is also the main vector for dengue and Zika
virus transmission. It is exquisitely well-adapted for this purpose:
Ae aegypti breeds in man-made containers of water, feeds
predominantly on human blood and bites multiple individuals
in a single blood meal, lives in close association with human
dwellings, and efﬁciently transmits YFV in its saliva.
The clinical manifestations of YF range from asymptomatic
infection to multi-organ failure and death. Most infections are
asymptomatic. Most symptomatic cases experience a self-limiting
febrile illness associated with myalgia, back pain, and prostration.
The fever, which lasts about 4 days, is accompanied by high levels
of viraemia, increasing the risk for mosquito infection during a
blood meal.6 Approximately 15–25% of infected individuals enter a
‘period of intoxication’ after a brief remission of fever. This is a
multisystem disease dominated by hepato-renal failure, profound
jaundice, and a bleeding diathesis. Death occurs in 20–50% of these
cases.6 This is a much higher mortality than dengue, which causes
death in 5% of patients, and as low as 1% in settings with experience
in dengue management.7 Morbidity in survivors is substantial,
with a prolonged convalescent phase characterized by weakness
and fatigue.
3. Epidemiology
YFV almost certainly originated in Africa.8 Its initial spread to
Central and South America, along with Ae aegypti, was a
consequence of the trans-Atlantic slave trade.9–12 The appalling
conditions on slave ships supported an intense and sustained
introduction of YFV into the Americas: hundreds of thousands of
West Africans were transported together with domesticated Ae
aegypti mosquitoes, which presumably set up breeding and
transmission cycles during the long voyages,13 delivering a critical
mass of viraemic hosts and vectors into a receptive environment.
This allowed for the establishment of enzootic YF in the forests
surrounding slave ports and its rapid dissemination throughout
the continent to become the most important epidemic disease in
the region for three centuries.14 Yellow fever epidemics hadsigniﬁcant impact as far north as Philadelphia in the 18th century.
The conditions for YF introduction into the Americas are not
dissimilar to the current scenario in Angola, where thousands of
foreign workers are rapidly transported via air to Asian cities that
have dense infestations of Ae aegypti vectors and unvaccinated
populations.
Epidemic YF in the Americas was successfully controlled in the
mid 20th century through mass vaccination and vector reduction
programmes.14,15 However, sporadic cases and small, limited
outbreaks continue to occur, associated with forest exposure.16
After a major resurgence in the region in the late 20th century,17
there now appears to be a downward trend of reported cases.18
Between 1985 and 2012, there were an estimated 4066 reported
cases and 2351 deaths from YF (58% case fatality rate) in the
Americas. Failure to sustain vector control and vaccination
programmes has led to the reinvasion of Ae aegypti across large
swaths of the Americas, as evidenced by ongoing chikungunya and
Zika outbreaks. If sufﬁcient YF cases occur in cities to facilitate
urban transmission, we may yet see YF epidemics again in the
Americas.
In Africa, YF continues to place an enormous burden on
communities living in endemic areas. Between 1980 and 2012,
150 yellow fever outbreaks in 26 African countries were reported
to the WHO, and over 90% of the estimated 200 000 annual global
cases occur on the continent. However, ﬁeld studies suggest that
the actual number of cases may be 10 to 500 times higher.19,20 This
is supported by a recent modelling study, which showed that YF
may infect up to 1.8 million individuals in Africa annually,
resulting in 180 000 (95% conﬁdence interval 51 000–380 000)
cases and 78 000 (95% conﬁdence interval 19 000–180 000)
deaths;21 this accounts for 0.8% of all-cause mortality in endemic
regions, and up to 3% in West Africa where most cases occur.21
Although complete eradication of YF is not possible due to the
sylvatic reservoir, signiﬁcant progress has been made with the
introduction of YF vaccine into routine child immunization
programmes.22 Mass vaccination has led to a 27% reduction in
overall annual burden and a 57% reduction in cases in targeted
countries.21 However, according to WHO and United Nations
Children’s Emergency Fund (UNICEF) estimates, only 41% of the
target population had received YF vaccination in 2014,23 well
below the recommended 80% threshold for the prevention of an
epidemic. In Angola, the YF vaccine coverage of 77% in 2014
(dropping to 70% in 2015), has clearly been inadequate to prevent
the current outbreak.
4. Re-emergence of yellow fever in the Americas and Africa:
implications for Asia
In dengue-endemic areas, the basic reproduction numbers (R0) of
YF and dengue are closely connected, suggesting that the introduc-
tion of a single YF-infected individual has the potential to trigger an
urban YF epidemic.24 This has been a concern in South American
countries where there has been a reinvasion by Ae aegypti in most
large cities.16,25,26 Although the last urban YF outbreak in South
America occurred in 1942 in Brazil, further cases of spill-over with
documented urban transmission have been reported in Bolivia27and
Paraguay.28 Both of these outbreaks were limited in space and time:
in Paraguay, a rapid national response with mass vaccinations and
surveillance terminated the outbreak.29
A similar situation exists in Africa, where there are regular large
epidemics involving partially immune populations living at the
forest–urban interface. This occurs mainly in West Africa, but even
Kenya has experienced a recent large sylvatic outbreak.30 During
urban epidemics in Africa, the incidence of infection is as high as
20%. Up to 40% of the affected population demonstrate serological
evidence of recent YF infection, which may reﬂect partial
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highlights the devastating potential of a YF introduction into a
completely non-immune population.
With increasing volumes of air travel, the international spread
of emerging and vector-borne infections has become a substantial
risk.29 This risk is particularly acute in the Asia-Paciﬁc region,
where systems for YF surveillance and detection are largely
untested, and YF vaccination is limited to travellers.14,16 The
volume of south-to-south travel – between Asia and South
America, or between Asia and Africa – has been less well-
documented. This has now become an important consideration, as
underscored by the chikungunya and Zika experience. For YF,
Africa, with over 90% of global YF cases, is the most likely source for
YF importations into Asia. The 10 YF cases reported in China
suggests that not all travellers were effectively vaccinated despite
Chinese public health regulations. The current conﬂuence of a
signiﬁcant urban YF outbreak in Angola together with a large
expatriate Chinese workforce (estimated at 20 000) with subopti-
mal vaccination levels may provide the ideal ecological conditions
for the introduction and urbanization of YFV in China and other
Asian countries. These reports of imported cases from Angola in
China therefore need to be taken extremely seriously.
5. Barriers to yellow fever introduction into Asia
Despite an abundance of people, monkeys, and Ae aegypti
throughout tropical and subtropical latitudes, yellow fever virus
has not previously been reported in Asia. In contrast, dengue virus
has established an urban transmission cycle in large populations in
the region, where it is now hyperendemic with major public health
and economic impacts. The failure of YF to become established in
the Asia-Paciﬁc is unexpected, given the closely shared disease
ecology with dengue. The actual epidemiological difference
suggests that local factors in the Asia-Paciﬁc have prevented YF
from gaining a foothold in the region, and may provide some
reassurance that there are sufﬁcient barriers to prevent the
establishment of YF in the Asia-Paciﬁc.
Urban outbreaks of YF are much less common in East Africa, and
are associated with enzootic YFV genotypes transmitted by
sylvatic mosquito vectors, rather than Ae aegypti.32 This suggests
that the East African Ae aegypti mosquitoes are less favourable
vectors for human disease and may therefore have limited
adaptation to human environments, reducing the possibilities
for survival during the long trade crossings by boat to Asia
historically.33 Phylogenetic data suggest that Ae aegypti may
eventually have reached Asia from the West, and not via the East
African trade route, and Asia thus probably became infested with
Ae aegypti later than the Americas.32,33
Additionally, there is some evidence of geographical variation
in Ae aegypti susceptibility to YF,34 raising the possibility that Asian
strains may be less competent YF vectors.8,26 Notwithstanding the
above limitations, there may have been importations of YF into
Asia after its widespread infestation with Ae aegypti, potentially
during the large African epidemics in Sudan,35 Ethiopia,36 and
Kenya.30 But, these would have involved few cases from isolated
rural and remote regions amongst populations unlikely to travel by
commercial airlines, and thus had a low potential for sustained or
transcontinental transmission.6,8,26,37 Together with delayed
historical introduction, this low risk of importation of viraemic
YF individuals to Asia has been the dominant explanation for the
absence of the disease in the region. However, it is less compelling
in the contemporary context of a large outbreak in a major urban
centre such as Luanda with direct ﬂight connections to Aedes-
infested cities in Asia.
The delayed and limited introduction of YF into Asia may have
left open an ecological niche for the establishment and dominanceof dengue and other ﬂaviviruses in the region through the native
Aedes albopictus, and later the well-adapted Ae aegypti mosquito.
This may have impacted on the ecology of YF in Asia in two key
ways. First, dengue virus may out-compete YFV within Ae
aegypti,37 either preventing co-infection or reducing infectiousness
by induction of a latently infected state.38,39 Second, the high
population seroprevalence of dengue and JE in Asia may provide
cross-protective immunity and act as a barrier to the establish-
ment of YF.6
In strong support of this hypothesis, experimental animals with
previous heterologous ﬂavivirus exposure experience lower levels
of viraemia and less severe disease when challenged with YFV.40,41
Thus, although the presence of heterotypic ﬂavivirus antibody does
not lower the risk of infection, dengue-immune individuals who
become infected with YF may be less likely to transmit YF to
mosquitoes. Using a mathematical transmission model, Amaku
and colleagues showed that YF prevalence is strongly affected by
cross-immunity, and that this best accounted for the absence of YF
in Asia compared with other competing hypotheses.42 This raises
the possibility that areas that are endemic but not hyperendemic
for dengue, such as southern China or Hong Kong and Singapore,
may be vulnerable to YF outbreaks, as the level of dengue and JE
immunity in the population may not be as complete as in other
parts of Southeast Asia. However, these ﬁndings do not explain the
presence of both dengue and urban YF in Africa, suggesting that
additional factors may have a role in the failure of YF to become a
dominant ﬂavivirus in Asia.
These other factors may relate to the YFV itself and its
transmission dynamics. YF has lower peak viral loads compared to
dengue,25 limiting its transmission potential in dengue-endemic
environments. And unlike dengue, YF has maintained is sylvatic
character. Urban transmission is thus always initiated by spill-over
from the jungle or savannah,26 and consequently may have a lower
risk of occurring in urban centres in Asia. The higher mortality of YF
may further limit its introduction and persistence in an urban cycle
and allow dengue to dominate in Asia.
A virological explanation for the lower frequency of YF
outbreaks in East Africa, and its absence in Asia, may be the
observed regional differences in YF viral genotypes,43 which
potentially inﬂuence virulence phenotypes in humans and non-
human primates.31,32 The genetic differences between geographic
strains of Ae aegypti inﬂuence its competence as a YF vector,44 and
it has been suggested that this also contributes to a lower YF
transmission risk in Asia.8,14,26 Finally, although it is possible that
humans and non-human primates in Asia have a lower genetic
susceptibility to YF, this has never been demonstrated.
6. Factors conducive to yellow fever entry into Asia
In the face of the above limitations, there is a modern precedent
for large-scale introduction of other Aedes-borne viral infections
into receptive populations. In 2004, a Kenyan outbreak of the
alphavirus chikungunya (CHIKV) spread via the India Ocean basin
to India and Southeast Asia, leading to an explosive epidemic
involving millions of people from populations with historical
CHIKV exposure.45 The same epidemic strain, which is spread by Ae
aegypti,46 is causing an ongoing chikungunya epidemic in the
Americas, and has already led to 39 000 infections this year. The
WHO has recently declared a Public Health Emergency of
International Concern in response to the Zika virus (ZIKV) outbreak
in the same region. Like YFV, ZIKV is a ﬂavivirus that originated in
Africa and is mainly transmitted by Ae aegypti. It entered South
America via the Paciﬁc in 2014, and has rapidly spread to infect
over a million people, with autochthonous cases reported from
26 countries47,48 by early April 2016. The Zika and chikungunya
epidemics provide powerful counterpoints to the most important
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shared vector and prior population exposure do not necessarily
constrain the entry of a new arbovirus into dengue-endemic
regions.
In the particular case of YF there are a number of other
contemporary factors that, when taken together, represent the
ideal conditions for an Asian epidemic. These are summarized in
Table 1. First, and perhaps the most critical, is the volume of
travellers entering the region on commercial airlines. This allows
for the introduction of symptomatic individuals during the period
of maximal viraemia, as well as those incubating the virus or
asymptomatically infected, raising the potential for transmission
to mosquito vectors. The Asia-Paciﬁc region will represent the
largest regional market for air transport in 2016,49 accounting for a
third of global passengers. Even a limited YF outbreak in China
could therefore rapidly disseminate to the higher risk regions of
India or Southeast Asia though air travel. Second, the ongoing
importation of YF-infected individuals into China in April 2016 is
nearing the peak period of dengue transmission, starting in July.5
The very high vector densities during this time may overcome
other barriers to YF urbanization, including the theoretical
possibility that Asian strains of Ae aegypti are less competent
than their African counterparts.50 Third, there appears to be low
effective vaccination coverage of Chinese workers in Angola. The
risk of illness for an unimmunized person spending 2 weeks in an
area of epidemic activity has been estimated at one in 267,51
translating into a substantial number of potential cases amongst
returning workers, with the consequence of sustained regional YF
exposure. Finally, there is a strong possibility that widespread
epidemic transmission could occur in Asia before it is recognized.16
This is related to the difﬁculty in YF diagnosis due to serological
cross-reactivity with prevalent ﬂaviviruses such as dengue and JE,
and a similar clinical presentation to other endemic diseases such
leptospirosis, typhoid fever, rickettsiosis, malaria, and viral
hepatitis.
Using the successful introduction and threats of re-emergence
of YF in South America as a historical model, there appear to be four
main conditions that need to be fulﬁlled to support YF introduction
into a new population: (1) sufﬁcient migratory ﬂow of viraemic
individuals from YF-endemic/epidemic areas (i.e., intense and
sustained introduction), (2) a high density of competent vectors in
receptive ecological conditions, (3) a susceptible or partially
susceptible human and monkey population, and (4) inadequateTable 1
Factors supporting the introduction of yellow fever into Asia
Risk factor C
Favourable local ecology A
f
u
Large numbers of returning travellers from an active outbreak in Angola T
A
i
High volumes of passenger air travel between an active epidemic
and China, and with other Asian countries
A
i
Possibly low vaccine coverage of Chinese workers U
Importation of cases during Aedes aegypti breeding season, starting July T
t
YF cases imported into dengue-endemic areas S
d
Difﬁculty in recognition of imported cases O
r
o
Inadequate vaccine stocks T
Poor surveillance structures A
s
p
m
YF, yellow fever.surveillance with delayed recognition leading to ineffective
vaccination programmes. Current conditions in many parts of
Asia therefore appear to be favourable for the introduction of YF
and the establishment of a transmission cycle in the region12
(Figure 1). In this context, the occurrence of YF cases from the
Angolan outbreak imported to China creates a situation primed for
an Asian epidemic, and demands an adequate response.
7. Responses to prevent yellow fever introduction into Asia
Actions in Central and South America in the early 20th century
demonstrated that urban YF epidemics can be successfully
prevented and controlled. As with other arboviruses, the tenets
underlying YF prevention are surveillance, vaccination, and vector
control. This should be coupled with the development of systems
that can support a rapid outbreak response. These include
strengthening laboratory capacity, the ability to carry out
epidemiological and entomological investigations, and emergency
measures to interrupt transmission, such as mass vaccination,
destruction of urban mosquito breeding sites, education about
mosquito avoidance, use of ovitraps, and domiciliary residual
spraying.57–60
The extent and nature of Ae aegypti infestation in Asia prohibits
the use of vector elimination as a feasible short-term intervention
for outbreak prevention,60 and so the urgent focus needs to be on
coordinated programmes of surveillance and vaccination of
travellers. Unfortunately, the high proportion of asymptomatic
infections and the non-speciﬁc nature of the mild clinical disease
limit the usefulness of passive surveillance to detect YF introduc-
tion into a new population. In the event of an outbreak in Asia, even
active case ﬁnding will be challenging in the context of overlapping
clinical presentation with other endemic infections and the
limitations in diagnostic tests described above. To mitigate these
limitations, governments could consider enforcing a 7-day
quarantine for returning travellers from endemic countries
without YF vaccination certiﬁcates. Most countries in the Asia-
Paciﬁc require proof of YF vaccination for travellers arriving from
countries with a risk of YF transmission,61 and this clearly needs to
be more strictly enforced after the importation of YF-infected
travellers to China. In response to this, the WHO has recommended
the reinforcement of vaccination requirements in China, and the
Chinese government has deployed teams to Angola to provide
vaccination to its citizens there. However, there is a delay ofomments
bundance of the primary mosquito vector, high human population density, and
orested areas with monkey hosts. This will support both an enzootic cycle and
rban transmission.
here are an estimated 20 000 Chinese workers in Angola, plus many from other
sian countries, including India. This could support sustained, high volume YF
ntroduction into Asia.
ir travel allows the introduction into China of viraemic cases or of people
ncubating YF, and facilitates subsequent dissemination within Asia.
nimmunized travellers increase the risk of infection and subsequent importation.
his will coincide with peak vector densities, increasing the risk for local
ransmission.
ix cases have been reported from Fujian Province, where the local transmission of
engue occurs with high Aedes aegypti concentrations.
verlapping clinical presentation with other endemic infections and cross-
eactivity of YF serology with other endemic ﬂaviviruses may delay the recognition
f an incipient epidemic.
he current vaccine supply would not support a full outbreak response in Asia.
sian laboratories are not geared for YF detection, airport screening is not
ufﬁciently sensitive for passive surveillance (misses cases in the incubation
eriod, fever masked by antipyretics), and there are limited numbers of travel
edicine experts.52
Loc ation of  yellow  fever cases  rel ated to  Angolan outb rea k, 27  April 2016Distribution of Ae aegypti
Luanda
Dubai
Beijing
Figure 1. Map showing the distribution of Ae aegypti across Africa and the Asia-Paciﬁc region53 (areas shaded pink). The red outline delineates yellow fever-endemic
regions.54 Yellow dots represent the location of yellow fever cases related to the Angolan outbreak (source: HealthMap).55 Commercial ﬂight routes with direct connections
between Luanda and Beijing and indirect connections from Luanda to South and Southeast Asia via Dubai (source: FLIRT)56 are also represented.
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vaccination, and surveillance for imported cases in Asia should be
ongoing. Unofﬁcial disease reporting systems, such as ProMED, are
becoming increasingly useful for the early detection and commu-
nication of new cases in emerging outbreaks, and have an
important role in raising situational awareness.
The most powerful tool in YF control is vaccination. Mass
vaccination campaigns are extremely effective at reducing the YF
burden in populations with low immunity, both in the prevention
of enzootic spill-over and in the rapid control of urban
epidemics.14,17,21 As of April 10, the Angolan government, together
with international partners, had administered 5.9 million doses of
YF vaccine in the Luanda province (accounting for 90% of the city’s
population); preparations for mass vaccination in Huambo and
Benguela provinces are underway. However, the global emergency
YF vaccine stockpile is depleted, and there is currently not enough
vaccine to cover Angola’s population. The production of new
vaccine using the current method of embryonated chicken eggs is
slow and limits capabilities to rapidly produce large vaccine
quantities in response to an outbreak. It is therefore highly unlikely
that sufﬁcient YF doses would be available for an effective
emergency YF outbreak response in Asia, further emphasizing the
vulnerability of the situation. Much lower doses of YF vaccine are
likely to be as effective as the currently used full-dose vaccine,62
and it has been suggested that a ﬁfth of the current dose should be
administered to expand vaccine stockpiles in the context of the
global threat posed by the current outbreak.63 This should be
considered seriously and implemented as a matter of urgency.
8. Conclusions
There is no single factor that accounts for the absence of YF in
Asia, and it is likely that a complex combination of virological,
environmental, and social processes have shaped the current
global epidemiology of YF restricting the disease to Africa and theAmericas. The current scenario of a YF outbreak in Angola, where
there is a large community of non-immune foreign nationals,
coupled with high volumes of air travel to an environment
conducive to transmission in Asia, is unprecedented in history.
These conditions raise the alarming possibility of a YF epidemic,
with a case fatality of up to 50%, in a region with a susceptible
population of two billion people and where there is extremely
limited infrastructure to respond effectively. The growing number
of imported cases in China shows how critical it is to recognize this
risk now in order to take adequate pre-emptive action so that a
global catastrophe can be averted.
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